Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells

Oekyung Kim, Tianyun Jiang, Yingqiu Xie, Zhiyong Guo, Hegang Chen, Yun Qiu

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

IL6 is a pleiotropic cytokine which has been implicated in ligand-independent activation of androgen receptor in prostate cancer cells. Here, we present the evidence that two cytoplasmic kinases Pim1 and Etk are involved in this process. We showed that Pim1 is expressed in all prostate cancer cell lines examined. Both the expression level and the kinase activity of Pim1 are regulated by IL6 in these cells. Furthermore, we showed that IL6 downstream tyrosine kinase Etk can induce tyrosine phosphorylation of Pim1 which is correlated with its kinase activity. Mutation of the conserved Tyrosine 218 in the activation loop results in reduced kinase activity of Pim1. Interestingly, Etk can also be activated by Pim1 when they are coexpressed in prostate cancer cells, suggesting a possible positive feedback loop between Etk and Pim1. It appears that both Pim1 and Etk are required for IL6-induced activation of androgen receptor-mediated transcription in prostate cancer cells because overexpression of the kinase-deficient form of either Pim1 or Etk dramatically blocks the IL6 effect. Coexpression of the two kinases together but neither one alone is sufficient to activate ARE-containing promoter. Taken together, our data suggest a synergism of Ser/Thr kinase Pim1 and tyrosine kinase Etk in IL6 signaling and provide new insights into ligand-independent activation of androgen receptor in prostate cancer cells.

Original languageEnglish
Pages (from-to)1838-1844
Number of pages7
JournalOncogene
Volume23
Issue number10
DOIs
Publication statusPublished - Mar 11 2004
Externally publishedYes

Fingerprint

Androgen Receptors
Interleukin-6
Prostatic Neoplasms
Phosphotransferases
Ligands
Protein-Tyrosine Kinases
Tyrosine
Phosphorylation
Cytokines
Cell Line
Mutation

Keywords

  • Androgen independence
  • Cytokine
  • Prostate cancer
  • Protein kinase

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. / Kim, Oekyung; Jiang, Tianyun; Xie, Yingqiu; Guo, Zhiyong; Chen, Hegang; Qiu, Yun.

In: Oncogene, Vol. 23, No. 10, 11.03.2004, p. 1838-1844.

Research output: Contribution to journalArticle

Kim, Oekyung ; Jiang, Tianyun ; Xie, Yingqiu ; Guo, Zhiyong ; Chen, Hegang ; Qiu, Yun. / Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. In: Oncogene. 2004 ; Vol. 23, No. 10. pp. 1838-1844.
@article{cba11fb6256c442fa5f5590fbdf39f72,
title = "Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells",
abstract = "IL6 is a pleiotropic cytokine which has been implicated in ligand-independent activation of androgen receptor in prostate cancer cells. Here, we present the evidence that two cytoplasmic kinases Pim1 and Etk are involved in this process. We showed that Pim1 is expressed in all prostate cancer cell lines examined. Both the expression level and the kinase activity of Pim1 are regulated by IL6 in these cells. Furthermore, we showed that IL6 downstream tyrosine kinase Etk can induce tyrosine phosphorylation of Pim1 which is correlated with its kinase activity. Mutation of the conserved Tyrosine 218 in the activation loop results in reduced kinase activity of Pim1. Interestingly, Etk can also be activated by Pim1 when they are coexpressed in prostate cancer cells, suggesting a possible positive feedback loop between Etk and Pim1. It appears that both Pim1 and Etk are required for IL6-induced activation of androgen receptor-mediated transcription in prostate cancer cells because overexpression of the kinase-deficient form of either Pim1 or Etk dramatically blocks the IL6 effect. Coexpression of the two kinases together but neither one alone is sufficient to activate ARE-containing promoter. Taken together, our data suggest a synergism of Ser/Thr kinase Pim1 and tyrosine kinase Etk in IL6 signaling and provide new insights into ligand-independent activation of androgen receptor in prostate cancer cells.",
keywords = "Androgen independence, Cytokine, Prostate cancer, Protein kinase",
author = "Oekyung Kim and Tianyun Jiang and Yingqiu Xie and Zhiyong Guo and Hegang Chen and Yun Qiu",
year = "2004",
month = "3",
day = "11",
doi = "10.1038/sj.onc.1207304",
language = "English",
volume = "23",
pages = "1838--1844",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells

AU - Kim, Oekyung

AU - Jiang, Tianyun

AU - Xie, Yingqiu

AU - Guo, Zhiyong

AU - Chen, Hegang

AU - Qiu, Yun

PY - 2004/3/11

Y1 - 2004/3/11

N2 - IL6 is a pleiotropic cytokine which has been implicated in ligand-independent activation of androgen receptor in prostate cancer cells. Here, we present the evidence that two cytoplasmic kinases Pim1 and Etk are involved in this process. We showed that Pim1 is expressed in all prostate cancer cell lines examined. Both the expression level and the kinase activity of Pim1 are regulated by IL6 in these cells. Furthermore, we showed that IL6 downstream tyrosine kinase Etk can induce tyrosine phosphorylation of Pim1 which is correlated with its kinase activity. Mutation of the conserved Tyrosine 218 in the activation loop results in reduced kinase activity of Pim1. Interestingly, Etk can also be activated by Pim1 when they are coexpressed in prostate cancer cells, suggesting a possible positive feedback loop between Etk and Pim1. It appears that both Pim1 and Etk are required for IL6-induced activation of androgen receptor-mediated transcription in prostate cancer cells because overexpression of the kinase-deficient form of either Pim1 or Etk dramatically blocks the IL6 effect. Coexpression of the two kinases together but neither one alone is sufficient to activate ARE-containing promoter. Taken together, our data suggest a synergism of Ser/Thr kinase Pim1 and tyrosine kinase Etk in IL6 signaling and provide new insights into ligand-independent activation of androgen receptor in prostate cancer cells.

AB - IL6 is a pleiotropic cytokine which has been implicated in ligand-independent activation of androgen receptor in prostate cancer cells. Here, we present the evidence that two cytoplasmic kinases Pim1 and Etk are involved in this process. We showed that Pim1 is expressed in all prostate cancer cell lines examined. Both the expression level and the kinase activity of Pim1 are regulated by IL6 in these cells. Furthermore, we showed that IL6 downstream tyrosine kinase Etk can induce tyrosine phosphorylation of Pim1 which is correlated with its kinase activity. Mutation of the conserved Tyrosine 218 in the activation loop results in reduced kinase activity of Pim1. Interestingly, Etk can also be activated by Pim1 when they are coexpressed in prostate cancer cells, suggesting a possible positive feedback loop between Etk and Pim1. It appears that both Pim1 and Etk are required for IL6-induced activation of androgen receptor-mediated transcription in prostate cancer cells because overexpression of the kinase-deficient form of either Pim1 or Etk dramatically blocks the IL6 effect. Coexpression of the two kinases together but neither one alone is sufficient to activate ARE-containing promoter. Taken together, our data suggest a synergism of Ser/Thr kinase Pim1 and tyrosine kinase Etk in IL6 signaling and provide new insights into ligand-independent activation of androgen receptor in prostate cancer cells.

KW - Androgen independence

KW - Cytokine

KW - Prostate cancer

KW - Protein kinase

UR - http://www.scopus.com/inward/record.url?scp=1842429920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842429920&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1207304

DO - 10.1038/sj.onc.1207304

M3 - Article

VL - 23

SP - 1838

EP - 1844

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 10

ER -